Evidence summaries
Peptide evidence summaries
What the peer-reviewed literature actually shows for peptides currently in circulation, and where each stands with FDA. Every source cited across these pages is peer-reviewed, published within the last fifteen years, and checked against the index for identity before publication.
These are not product pages. ExaVeyra does not supply the substances described here, and nothing on them is medical advice or an offer to sell.
On FDA’s category 2 designation
FDA’s interim policy sorts bulk substances nominated for compounding into three categories. Category 2 means the substance was nominated with enough information for FDA to evaluate it, and that the agency identified significant safety risks. It currently lists 17 substances relevant to this catalogue. Category 3, by contrast, means FDA could not evaluate the substance at all, so absence from category 2 is not clearance.
FDA source , checked 2026-08-10
The pages
Ten evidence summaries. Some cover a single molecule, others a family where the comparison is more useful than three separate pages.
- BPC-157FDA 503A category 2
A synthetic 15-residue peptide derived from a human gastric protein, studied almost entirely in animals, and listed by FDA as a category 2 bulk substance.
1 substance
- Kisspeptin-10FDA 503A category 2
Mainstream reproductive endocrinology with human administration studies, and still FDA category 2. The clearest illustration that strong science and a safe compounded preparation are different questions.
1 substance
- TB-500FDA 503A category 2
A seven-residue fragment routinely marketed on research into thymosin beta-4, a 43-residue protein. The two are not the same molecule.
1 substance
- MOTS-cFDA 503A category 2
One of a small group of peptides encoded inside mitochondrial DNA rather than the nucleus. Strong mechanistic literature, human data still observational.
1 substance
- Growth hormone secretagoguesFDA 503A category 2
Three routes to one axis, compared against the approved drugs that already act on it. FDA’s rationales for the three differ sharply, and two describe events rather than absent data.
3 substances
- Semax and selankFDA 503A category 2
A substantial literature that has barely been replicated outside the research tradition that produced it, which is a different problem from a literature that failed.
2 substances
- Fragment peptidesFDA 503A category 2
Pieces of larger proteins, marketed on the parent’s research. Much of the fragment-specific literature exists because anti-doping laboratories needed to detect them.
2 substances
- EpitalonFDA 503A category 2
A four-residue peptide sold on a telomerase claim specific enough to test. It has been tested in human cell lines, which is not the same as a clinical finding.
1 substance
- DSIPFDA 503A category 2
Named in 1977 for an effect five decades have not firmly established in people. FDA lists it as emideltide, so searching that list for DSIP finds nothing.
1 substance
- DihexaFDA 503A category 2
FDA states it identified no human exposure data by any route. One of only two substances on the list carrying that specific wording.
1 substance
Substances covered
Listed by substance, for looking up a specific name. Some pages cover several related compounds together, in which case the link goes to the section treating that one.
| Substance | FDA status | Covered in |
|---|---|---|
| AOD-9604 | 503A category 2 | Fragment peptides |
| BPC-157 | 503A category 2 | BPC-157 |
| CJC-1295 | 503A category 2 | Growth hormone secretagogues |
| Dihexa | 503A category 2 | Dihexa |
| DSIP (emideltide) | 503A category 2 | DSIP |
| Epitalon | 503A category 2 | Epitalon |
| Ibutamoren (MK-677) | 503A category 2 | Growth hormone secretagogues |
| Ipamorelin | 503A category 2 | Growth hormone secretagogues |
| Kisspeptin-10 | 503A category 2 | Kisspeptin-10 |
| MOTS-c | 503A category 2 | MOTS-c |
| PEG-MGF | 503A category 2 | Fragment peptides |
| Selank | 503A category 2 | Semax and selank |
| Semax | 503A category 2 | Semax and selank |
| TB-500 | 503A category 2 | TB-500 |